Publicaciones en colaboración con investigadores/as de Fundación Jiménez Díaz (47)

2024

  1. Childhood-Onset Non-Infectious Uveitis in the “Biologic Era”. Results From Spanish Multicenter Multidisciplinary Real-World Clinical Settings

    Ocular Immunology and Inflammation, Vol. 32, Núm. 9, pp. 2159-2169

  2. Mean Platelet Volume Is Related to Cumulative Disease Damage in Patients with Systemic Lupus Erythematosus

    Life, Vol. 14, Núm. 4

  3. Personalized cardiovascular risk assessment in Rheumatoid Arthritis patients using circulating molecular profiles and their modulation by TNFi, IL6Ri, and JAKinibs

    Biomedicine and Pharmacotherapy, Vol. 173

  4. Positron Emission Tomography/Computed Tomography in Polymyalgia Rheumatica: When and for What—A Critical Review

    Diagnostics, Vol. 14, Núm. 14

2023

  1. 18F-Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography Findings of Polymyalgia Rheumatica in Patients with Giant Cell Arteritis

    Journal of Clinical Medicine, Vol. 12, Núm. 22

  2. Positron Emission Computed Tomography Spectrum of Large Vessel Vasculitis in a Tertiary Center: Differences in 18F-fluorodeoxyglucose Uptake between Large Vessel Vasculitis with Predominant Cranial and Extracranial Giant Cell Arteritis Phenotypes

    Journal of Clinical Medicine, Vol. 12, Núm. 19

  3. The Ratio of Monocytes to HDL-Cholesterol Is Associated with Cardiovascular Risk and Insulin Resistance in Patients with Rheumatoid Arthritis

    LIFE-BASEL, Vol. 13, Núm. 10

2022

  1. Inmune-mediated inflammatory rheumatic diseases in transgender people: A scoping review

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Myo-Spain: Spanish Registry of Patients with Idiopathic Inflammatory Myopathy. Methodology

    Reumatologia Clinica, Vol. 18, Núm. 5, pp. 253-259

2021

  1. EULAR recommendations for intra-articular therapies

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 10, pp. 1299-1305

  2. EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs)

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 7, pp. 840-847

  3. Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: An overview of systematic reviews

    RMD Open, Vol. 7, Núm. 2

  4. HLA association with the susceptibility to anti-synthetase syndrome

    Joint Bone Spine, Vol. 88, Núm. 3

  5. Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome

    Scientific Reports, Vol. 11, Núm. 1

  6. Safety in the use of ultrasound in rheumatology during the COVID-19 Pandemic. Spanish Society of Rheumatology positioning paper

    Reumatologia Clinica, Vol. 17, Núm. 5, pp. 284-289

2020

  1. Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure

    Reumatologia Clinica, Vol. 16, Núm. 5, pp. 345-352

  2. Influence of MUC5B gene on antisynthetase syndrome

    Scientific Reports, Vol. 10, Núm. 1

2017

  1. A multicentric study to evaluate the use of relative retention times in targeted proteomics

    Journal of Proteomics, Vol. 152, pp. 138-149

  2. Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Six-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

    Arthritis and Rheumatology, Vol. 69, Núm. 1, pp. 77-85

  3. Exploring the remission concept in rheumatoid arthritis with patients and rheumatologists: Time for a new approach?

    Clinical and Experimental Rheumatology, Vol. 35, Núm. 5, pp. 816-822